1. alt/ast \>5 times the upper limit of normal. 2. patients with respiratory rate \<20 breaths/min and normal spo2 with confirmed sars-cov-2 infection as determined by pcr (mild covid-19 subjects). 3. patients with respiratory rate ≥30 breaths/min and spo2 at rest ≤93% (severe covid-19 subjects). 4. stage ≥4 severe chronic kidney disease or requiring dialysis (i.e. egfr \<30 ml/min/1.73 m2). 5. pregnant or breast feeding. 6. allergy to any study medication or usage of test drug during last 14 days prior to screening 7. severe co-morbidity (e.g. uncontrolled hypertension and uncontrolled dm, systemic disease which affect the vital organs severity, immunocompromised patients etc.) as per investigator's assessment. 8. comorbid condition like myocardial infarction or heart failure within 90 days of recruitment. 9. prolong qt interval (\>450 ms).

1. alt/ast \>5 times the upper limit of normal. 2. patients with respiratory rate \<20 breaths/min and normal spo2 with confirmed sars-cov-2 infection as determined by pcr (mild covid-19 subjects). 3. patients with respiratory rate ≥30 breaths/min and spo2 at rest ≤93% (severe covid-19 subjects). 4. stage ≥4 severe chronic kidney disease or requiring dialysis (i.e. egfr \<30 ml/min/1.73 m2). 5. pregnant or breast feeding. 6. allergy to any study medication or usage of test drug during last 14 days prior to screening 7. severe co-morbidity (e.g. uncontrolled hypertension and uncontrolled dm, systemic disease which affect the vital organs severity, immunocompromised patients etc.) as per investigator's assessment. 8. comorbid condition like myocardial infarction or heart failure within 90 days of recruitment. 9. prolong qt interval (\>450 ms).

alt/ast >5 times the upper limit of normal. patients with respiratory rate <20 breaths/min and normal spo2 with confirmed sars-cov-2 infection as determined by pcr (mild covid-19 subjects). patients with respiratory rate ≥30 breaths/min and spo2 at rest ≤93% (severe covid-19 subjects). stage ≥4 severe chronic kidney disease or requiring dialysis (i.e. egfr <30 ml/min/1.73 m2). pregnant or breast feeding. allergy to any study medication or usage of test drug during last 14 days prior to screening severe co-morbidity (e.g. uncontrolled hypertension and uncontrolled dm, systemic disease which affect the vital organs severity, immunocompromised patients etc.) as per investigator's assessment. comorbid condition like myocardial infarction or heart failure within 90 days of recruitment. prolong qt interval (>450 ms).

alt/ast >5 times the upper limit of normal. patients with respiratory rate <20 breaths/min and normal spo2 with confirmed sars-cov-2 infection as determined by pcr (mild covid-19 subjects). patients with respiratory rate ≥30 breaths/min and spo2 at rest ≤93% (severe covid-19 subjects). stage ≥4 severe chronic kidney disease or requiring dialysis (i.e. egfr <30 ml/min/1.73 m2). pregnant or breast feeding. allergy to any study medication or usage of test drug during last 14 days prior to screening severe co-morbidity (e.g. uncontrolled hypertension and uncontrolled dm, systemic disease which affect the vital organs severity, immunocompromised patients etc.) as per investigator's assessment. comorbid condition like myocardial infarction or heart failure within 90 days of recruitment. prolong qt interval (>450 ms).

1. alt/ast >5 times the upper limit of normal. 2. patients with respiratory rate <20 breaths/min and normal spo2 with confirmed sars-cov-2 infection as determined by pcr (mild covid-19 subjects). 3. patients with respiratory rate ≥30 breaths/min and spo2 at rest ≤93% (severe covid-19 subjects). 4. stage ≥4 severe chronic kidney disease or requiring dialysis (i.e. egfr <30 ml/min/1.73 m2). 5. pregnant or breast feeding. 6. allergy to any study medication or usage of test drug during last 14 days prior to screening 7. severe co-morbidity (e.g. uncontrolled hypertension and uncontrolled dm, systemic disease which affect the vital organs severity, immunocompromised patients etc.) as per investigator's assessment. 8. comorbid condition like myocardial infarction or heart failure within 90 days of recruitment. 9. prolong qt interval (>450 ms).

1. alt/ast >5 times the upper limit of normal. 2. patients with respiratory rate <20 breaths/min and normal spo2 with confirmed sars-cov-2 infection as determined by pcr (mild covid-19 subjects). 3. patients with respiratory rate ≥30 breaths/min and spo2 at rest ≤93% (severe covid-19 subjects). 4. stage ≥4 severe chronic kidney disease or requiring dialysis (i.e. egfr <30 ml/min/1.73 m2). 5. pregnant or breast feeding. 6. allergy to any study medication or usage of test drug during last 14 days prior to screening 7. severe co-morbidity (e.g. uncontrolled hypertension and uncontrolled dm, systemic disease which affect the vital organs severity, immunocompromised patients etc.) as per investigator's assessment. 8. comorbid condition like myocardial infarction or heart failure within 90 days of recruitment. 9. prolong qt interval (>450 ms).